Literature DB >> 25336694

Molecular pathways: targeting the kinase effectors of RHO-family GTPases.

Tatiana Y Prudnikova1, Sonali J Rawat2, Jonathan Chernoff3.   

Abstract

RHO GTPases, members of the RAS superfamily of small GTPases, are adhesion and growth factor-activated molecular switches that play important roles in tumor development and progression. When activated, RHO-family GTPases such as RAC1, CDC42, and RHOA, transmit signals by recruiting a variety of effector proteins, including the protein kinases PAK, ACK, MLK, MRCK, and ROCK. Genetically induced loss of RHO function impedes transformation by a number of oncogenic stimuli, leading to an interest in developing small-molecule inhibitors that either target RHO GTPases directly, or that target their downstream protein kinase effectors. Although inhibitors of RHO GTPases and their downstream signaling kinases have not yet been widely adopted for clinical use, their potential value as cancer therapeutics continues to facilitate pharmaceutical research and development and is a promising therapeutic strategy. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25336694      PMCID: PMC4286478          DOI: 10.1158/1078-0432.CCR-14-0827

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  64 in total

1.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

Authors:  Louis J Lombardo; Francis Y Lee; Ping Chen; Derek Norris; Joel C Barrish; Kamelia Behnia; Stephen Castaneda; Lyndon A M Cornelius; Jagabandhu Das; Arthur M Doweyko; Craig Fairchild; John T Hunt; Ivan Inigo; Kathy Johnston; Amrita Kamath; David Kan; Herbert Klei; Punit Marathe; Suhong Pang; Russell Peterson; Sidney Pitt; Gary L Schieven; Robert J Schmidt; John Tokarski; Mei-Li Wen; John Wityak; Robert M Borzilleri
Journal:  J Med Chem       Date:  2004-12-30       Impact factor: 7.446

2.  Virtual screening approach for the identification of new Rac1 inhibitors.

Authors:  Nicola Ferri; Alberto Corsini; Paolo Bottino; Francesca Clerici; Alessandro Contini
Journal:  J Med Chem       Date:  2009-07-23       Impact factor: 7.446

3.  ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma.

Authors:  Victoria Sanz-Moreno; Cedric Gaggioli; Maggie Yeo; Jean Albrengues; Fredrik Wallberg; Amaya Viros; Steven Hooper; Richard Mitter; Chloé C Féral; Martin Cook; James Larkin; Richard Marais; Guerrino Meneguzzi; Erik Sahai; Chris J Marshall
Journal:  Cancer Cell       Date:  2011-08-16       Impact factor: 31.743

4.  Transforming mutations of RAC guanosine triphosphatases in human cancers.

Authors:  Masahito Kawazu; Toshihide Ueno; Kenji Kontani; Yoshitaka Ogita; Mizuo Ando; Kazutaka Fukumura; Azusa Yamato; Manabu Soda; Kengo Takeuchi; Yoshio Miki; Hiroyuki Yamaguchi; Takahiko Yasuda; Tomoki Naoe; Yoshihiro Yamashita; Toshiaki Katada; Young Lim Choi; Hiroyuki Mano
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

5.  MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation.

Authors:  Deborah N Chadee; John M Kyriakis
Journal:  Nat Cell Biol       Date:  2004-07-18       Impact factor: 28.824

6.  A novel multi-modal drug repurposing approach for identification of potent ACK1 inhibitors.

Authors:  Sharangdhar S Phatak; Shuxing Zhang
Journal:  Pac Symp Biocomput       Date:  2013

7.  A chemical and phosphoproteomic characterization of dasatinib action in lung cancer.

Authors:  Jiannong Li; Uwe Rix; Bin Fang; Yun Bai; Arthur Edwards; Jacques Colinge; Keiryn L Bennett; Jingchun Gao; Lanxi Song; Steven Eschrich; Giulio Superti-Furga; John Koomen; Eric B Haura
Journal:  Nat Chem Biol       Date:  2010-02-28       Impact factor: 15.040

8.  Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation.

Authors:  Patricia L Podolin; James F Callahan; Brian J Bolognese; Yue H Li; Karey Carlson; T Gregg Davis; Geoff W Mellor; Christopher Evans; Amy K Roshak
Journal:  J Pharmacol Exp Ther       Date:  2004-08-17       Impact factor: 4.030

9.  Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities.

Authors:  R A Patel; Y Liu; B Wang; R Li; S M Sebti
Journal:  Oncogene       Date:  2013-02-11       Impact factor: 9.867

10.  Targeting Cdc42 with the small molecule drug AZA197 suppresses primary colon cancer growth and prolongs survival in a preclinical mouse xenograft model by downregulation of PAK1 activity.

Authors:  Karin Zins; Sandun Gunawardhana; Trevor Lucas; Dietmar Abraham; Seyedhossein Aharinejad
Journal:  J Transl Med       Date:  2013-11-27       Impact factor: 5.531

View more
  23 in total

Review 1.  Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases.

Authors:  Ivona Aksentijevich; Oskar Schnappauf
Journal:  Nat Rev Rheumatol       Date:  2021-05-25       Impact factor: 20.543

Review 2.  Dynamic interplay between adhesion surfaces in carcinomas: Cell-cell and cell-matrix crosstalk.

Authors:  Yvonne E Smith; Sri HariKrishna Vellanki; Ann M Hopkins
Journal:  World J Biol Chem       Date:  2016-02-26

Review 3.  StarD13: a potential star target for tumor therapeutics.

Authors:  Leila Jaafar; Zeinab Chamseddine; Mirvat El-Sibai
Journal:  Hum Cell       Date:  2020-04-09       Impact factor: 4.174

4.  The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin.

Authors:  Tatiana Y Prudnikova; Jonathan Chernoff
Journal:  Small GTPases       Date:  2016-07-18

Review 5.  Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy.

Authors:  Claire Vennin; Nicola Rath; Marina Pajic; Michael F Olson; Paul Timpson
Journal:  Small GTPases       Date:  2017-10-03

6.  16p11.2 deletion is associated with hyperactivation of human iPSC-derived dopaminergic neuron networks and is rescued by RHOA inhibition in vitro.

Authors:  Hannah Pinson; Richard S Smith; Maria Sundberg; Kellen D Winden; Pooja Venugopal; Derek J C Tai; James F Gusella; Michael E Talkowski; Christopher A Walsh; Max Tegmark; Mustafa Sahin
Journal:  Nat Commun       Date:  2021-05-18       Impact factor: 14.919

7.  Breast Tumor Kinase (Brk/PTK6) Mediates Advanced Cancer Phenotypes via SH2-Domain Dependent Activation of RhoA and Aryl Hydrocarbon Receptor (AhR) Signaling.

Authors:  Amy R Dwyer; Carlos Perez Kerkvliet; Raisa I Krutilina; Hilaire C Playa; Tiffany N Seagroves; Carol A Lange; Deanna N Parke; Warner A Thomas; Branden A Smeester; Branden S Moriarity
Journal:  Mol Cancer Res       Date:  2020-11-10       Impact factor: 6.333

8.  Lichen Secondary Metabolite, Physciosporin, Inhibits Lung Cancer Cell Motility.

Authors:  Yi Yang; So-Yeon Park; Thanh Thi Nguyen; Young Hyun Yu; Tru Van Nguyen; Eun Gene Sun; Jayalal Udeni; Min-Hye Jeong; Iris Pereira; Cheol Moon; Hyung-Ho Ha; Kyung Keun Kim; Jae-Seoun Hur; Hangun Kim
Journal:  PLoS One       Date:  2015-09-15       Impact factor: 3.240

9.  B3GNT3 acts as a carcinogenic factor in endometrial cancer via facilitating cell growth, invasion and migration through regulating RhoA/RAC1 pathway-associated markers.

Authors:  Ji-Shui Wang; Fang Ruan; Li-Zhu Guo; Feng-Ge Wang; Fu-Ling Wang; Hong-Min An
Journal:  Genes Genomics       Date:  2021-03-08       Impact factor: 1.839

10.  Hhex inhibits cell migration via regulating RHOA/CDC42-CFL1 axis in human lung cancer cells.

Authors:  Xiaopeng Li; Guilin Ma; Wenjie Guo; Ning Mu; Yingying Wang; Xiangguo Liu; Ling Su
Journal:  Cell Commun Signal       Date:  2021-07-28       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.